A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2in AML induction: Results from the UK NCRI AML17 trial in 1206 patients

Blood

Volumn 125, Issue 25, 2015, Pages 3878-3885

  Burnett, Alan K ^a   Russell, Nigel H ^b   Hills, Robert K ^a   Kell, Jonathan ^c   Cavenagh, Jamie ^d   Kjeldsen, Lars ^e   McMullin, Mary Frances ^f   Cahalin, Paul ^g   Dennis, Mike ^h   Friis, Lone ⁱ   Thomas, Ian F ^a   Milligan, Don ^j   Clark, Richard E ^k  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f BELFAST CITY HOSPITAL   (United Kingdom)

^g BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^k ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; EVEROLIMUS; GEMTUZUMAB OZOGAMICIN; LESTAURTINIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; FLT3 GENE; GASTROINTESTINAL TOXICITY; GENE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; AGED; CLINICAL TRIAL; DOSE RESPONSE; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84932615484     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-623447     Document Type: Article

References (26)

1. Castaigne S, Pautas C, Terré C, et al Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
2. Récher C, Béné MC, Lioure B, et al; Groupe Ouest-Est d' étude des Leucé mies Aiguës et autres. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia. 2014;28(2):440-443.
3. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397-5403.
4. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28(2):289-292.
5. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program. 2012;2012:1-6.
6. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013;31(27):3360-3368.
7. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30(20):2441-2448.
8. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
9. Bishop JF, Lowenthal RM, Joshua D, et al Australian Leukemia Study Group. Etoposide in acute nonlymphocytic leukemia. Blood. 1990;75(1):27-32.
10. th AML trial (MRC AML10). Blood. 1997;89(7):2311-2318.
11. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996.
12. Wheatley K. A systemic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol. 1998;103(1):100-109.
13. Sekine L, Morais VD, Lima KM, Onsten TG, Ziegelmann PK, Ribeiro RA. Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients [published online ahead of print November 3, 2014]. Hematol Oncol. doi:10.1002/hon.2173.
14. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87(5):1710-1717.
15. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8):2841-2851.
16. Löwenberg B, Pabst T, Vellenga E, et al Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036.
17. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
18. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
19. Löwenberg B, Ossenkoppele GJ, van Putten W, et al Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
20. Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14):3832-3841.
21. Devillier R, Bertoli S, Prebet T, et al. Induction therapy for AML patients with daunorubicin dose of 60 mg/m2 and 90 mg/m2 results in similar complete response rate, relapse-free and overall survival. Blood. 2013;122(1):6.
22. Burnett AK, Hills RK, Wheatley K, et al. A sensitive risk score for directing treatment in younger patients with AML [abstract]. Blood. 2006;108(11). Abstract 18.
23. Grimwade D, Walker H, Oliver F, et al The Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333.
24. Cheson BD, Bennett JM, Kopecky KJ, et al International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
25. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838-4841.
26. Luskin MR, Lee J-W, Fernandez HF, et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavourable cytogenetic risk and FLT3-ITD mutant AML: updated analysis from Eastern Cooperative Oncology Trial E1900 [abstract]. Blood. 2014;124(21). Abstract 373.